SRR602540
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.418
- MYOGENESIS+0.276
- SPERMATOGENESIS+0.264
- APICAL_JUNCTION+0.211
- WNT_BETA_CATENIN_SIGNALING+0.169
- ESTROGEN_RESPONSE_EARLY+0.137
- PANCREAS_BETA_CELLS+0.128
- ESTROGEN_RESPONSE_LATE+0.115
- KRAS_SIGNALING_UP+0.103
- UV_RESPONSE_DN+0.076
Top 10 suppressed
- MYC_TARGETS_V1-0.616
- UNFOLDED_PROTEIN_RESPONSE-0.542
- DNA_REPAIR-0.519
- E2F_TARGETS-0.488
- MYC_TARGETS_V2-0.485
- OXIDATIVE_PHOSPHORYLATION-0.476
- MTORC1_SIGNALING-0.466
- G2M_CHECKPOINT-0.414
- TNFA_SIGNALING_VIA_NFKB-0.410
- PROTEIN_SECRETION-0.404
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1339549 | GTEX | — | 0.927 |
| 2 | SRR1336006 | GTEX | — | 0.921 |
| 3 | SRR1402454 | GTEX | — | 0.919 |
| 4 | SRR1434138 | GTEX | — | 0.916 |
| 5 | SRR1475257 | GTEX | — | 0.911 |
| 6 | SRR1457597 | GTEX | — | 0.910 |
| 7 | SRR614155 | GTEX | — | 0.910 |
| 8 | SRR1339530 | GTEX | — | 0.910 |
| 9 | SRR1419714 | GTEX | — | 0.907 |
| 10 | SRR1394713 | GTEX | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.418 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.276 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.264 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.211 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.169 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.137 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.128 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.115 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.103 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.076 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.063 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.057 | Remibrutinib | — uncovered |
| COAGULATION | 0.055 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.041 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.036 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.033 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.028 | Temsirolimus | — uncovered |